Impact of percutaneous patent foramen ovale closure on migraine headaches in patients with history of ischemic neurological events
| Autor: | Katarzyna Spisak-Borowska, Tomasz Bochenek, Grzegorz Bajor, Jerzy Machowski, Katarzyna Mizia-Stec, Ewa Konarska-Kuszewska, Joel P. Giblett, Węglarz Przemysław, Patrick A. Calvert, Maria Trusz-Gluza |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Percutaneous patent foramen ovale 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Clinical endpoint migraine In patient Closure (psychology) Stroke Original Paper patent foramen ovale closure business.industry medicine.disease stroke Migraine Cardiology Patent foramen ovale Medicine Headaches medicine.symptom Cardiology and Cardiovascular Medicine business headache 030217 neurology & neurosurgery |
| Zdroj: | Advances in Interventional Cardiology, Vol 16, Iss 3, Pp 315-320 (2020) Postępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology |
| ISSN: | 1734-9338 |
| Popis: | Introduction Observational studies have shown that migraine has been associated with patent foramen ovale (PFO). Whilst studies investigating PFO closure for the treatment of migraine have been neutral, there is some evidence that symptoms of migraine may improve if the PFO was closed after ischemic stroke. Aim To establish whether closure of PFO in patients with stroke or transient ischemic attack (TIA) is associated with reduction in the severity of co-existent migraine headaches. Material and methods Patients with ischemic stroke or TIA, PFO suitable for percutaneous closure and migraine, were given migraine severity questionnaires prior to PFO closure. These were followed up at 6 and 12 months after closure with the same questionnaire. The primary endpoint was change in migraine severity using the Migraine Severity Scale (MIGSEV). Migraine episode frequency, disability (using the MIDAS scale), and pain intensity were also assessed. Results Sixty-two patients were included in the analysis. MIGSEV scores reduced from 7 (7–8) at baseline to 4 (3.25–6) at 6-month follow-up, and 3 (0–4) at 12-month follow-up (p < 0.001). Other measures of migraine headache were also improved at both 6- and 12-month follow-up. Twenty-four (38%) patients were rendered migraine free at 12 months. Conclusions PFO closure for stroke or TIA prevention in patients with migraine was associated with a reduction in markers of migraine headache severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|